Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 130

Sort by

Sort Order Select

Journal Articles

Ubtf tandem Duplications Define a Novel Subtype of Acute Myeloid Leukemia Associated with Younger Age, WT1 Mutations and HOXA9 Marked Overexpression

Helena Castellet, Guillermo Ramil López, Ana Garrido, Alícia Artigas-Baleri, Marta Pratcorona, Olga Salamero, Albert Cortés-Bullich, Susana Vives, Mar Tormo, Martin Mascaro Riera, David Gallardo, Josep Maria Marti Tutusaus, Antonio Garcia, Jorge Sierra, Jordi Esteve, Josep Nomdedeu

Blood (2023) 142 (Supplement 1): 6045.

https://doi.org/10.1182/blood-2023-186064

Published: 2023

Journal Articles

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Blood (2023) 142 (Supplement 1): 62.

https://doi.org/10.1182/blood-2023-183029

Published: 2023

Journal Articles

Phase 1 Clinical Trial of Memory-Enriched Academic HSP-CAR30 for the Treatment of Relapsed/Refractory Hodgkin Lymphoma and CD30 + T-Cell Lymphoma: Clinical and Biological Studies

Ana Carolina Carolina Caballero Gonzalez, Laura Escribà-García, Rosanna Montserrat, Eva Escudero-López, Paula Pujol-Fernández, Cristina Ujaldón-Miró, Irene García-Cadenas, Albert Esquirol, Rodrigo Martino, Jorge Sierra, Carmen Alvarez-Fernández, Javier Briones

Blood (2022) 140 (Supplement 1): 405–407.

https://doi.org/10.1182/blood-2022-167504

Published: 2022

Journal Articles

Autologous Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia - a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Blood (2022) 140 (Supplement 1): 4848–4850.

https://doi.org/10.1182/blood-2022-166166

Published: 2022

Journal Articles

Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration

Blood (2022) 140 (Supplement 1): 6053–6055.

https://doi.org/10.1182/blood-2022-165088

Published: 2022

Journal Articles

RAS Mutations in Adult Acute Myeloid Leukemia (AML). Frequency, Mutational Spectrum, and Identification of a Comutation Bias for KRAS K117 ( TET2 / ASXL1 )

Blood (2022) 140 (Supplement 1): 11821–11823.

https://doi.org/10.1182/blood-2022-164718

Published: 2022

Journal Articles

Bone Marrow WT1 mRNA Upregulation in Acute Myeloid Leukemia (AML) in Complete Molecular Remission (mCR): Understanding the Limitations and Advantages of WT1 As a Measurable Residual Disease (MRD) Target

Albert Esquirol, Yolanda Guillén, Elena Bussaglia, Vanesa Criado, Maite Carricondo, Pamela Acha, Manel Esteller, Jorge Sierra, Francesc Solé, Anna Bigas, Josep F Nomdedeu

Blood (2022) 140 (Supplement 1): 11786–11787.

https://doi.org/10.1182/blood-2022-166117

Published: 2022

Journal Articles

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

Blood (2022) 140 (12): 1345–1377.

https://doi.org/10.1182/blood.2022016867

Published: 2022

Journal Articles

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian, Michael J. Borowitz, Katherine R. Calvo, Hans-Michael Kvasnicka, Sa A. Wang, Adam Bagg, Tiziano Barbui, Susan Branford, Carlos E. Bueso-Ramos, Jorge E. Cortes, Paola Dal Cin, Courtney D. DiNardo, Hervé Dombret, Eric J. Duncavage, Benjamin L. Ebert, Elihu H. Estey, Fabio Facchetti, Kathryn Foucar, Naseema Gangat, Umberto Gianelli, Lucy A. Godley, Nicola Gökbuget, Jason Gotlib, Eva Hellström-Lindberg, Gabriela S. Hobbs, Ronald Hoffman, Elias J. Jabbour, Jean-Jacques Kiladjian, Richard A. Larson, Michelle M. Le Beau, Mignon L.-C. Loh, Bob Löwenberg, Elizabeth Macintyre, Luca Malcovati, Charles G. Mullighan, Charlotte Niemeyer, Olatoyosi M. Odenike, Seishi Ogawa, Alberto Orfao, Elli Papaemmanuil, Francesco Passamonti, Kimmo Porkka, Ching-Hon Pui, Jerald P. Radich, Andreas Reiter, Maria Rozman, Martina Rudelius, Michael R. Savona, Charles A. Schiffer, Annette Schmitt-Graeff, Akiko Shimamura, Jorge Sierra, Wendy A. Stock, Richard M. Stone, Martin S. Tallman, Jürgen Thiele, Hwei-Fang Tien, Alexandar Tzankov, Alessandro M. Vannucchi, Paresh Vyas, Andrew H. Wei, Olga K. Weinberg, Agnieszka Wierzbowska, Mario Cazzola, Hartmut Döhner, Ayalew Tefferi

Blood (2022) 140 (11): 1200–1228.

https://doi.org/10.1182/blood.2022015850

Published: 2022

Includes: Supplemental data

Journal Articles

Follow-up of patients with R/R FLT3- mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

Blood (2022) 139 (23): 3366–3375.

https://doi.org/10.1182/blood.2021011583

Published: 2022

Includes: Supplemental data

Journal Articles

Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation

Blood (2021) 138 (Supplement 1): 4041.

https://doi.org/10.1182/blood-2021-149521

Published: 2021

Journal Articles

Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study

Tommaso Matteuzzi, Daniele Dall'Olio, Eric Sträng, Alessandra Merlotti, Javier Martinez Elicegui, Axel Benner, Maral Saadati, Julia Krzykalla, Caroline A. Heckman, Ana Heredia Casanoves, Jurjen Versluis, María Abáigar, Alberto Hernandez-Sanchez, Laura Jamilis, Peter JM Valk, Klaus H. Metzeler, Rosa Ayala, Joaquin Martinez Lopez, Herve Dombret, Pau Montesinos, Jorge Sierra, Claude Preudomme, Frederick Damm, Ken I Mills, Raúl Azibeiro Melchor, Jiří Mayer, Christian Thiede, Maria Teresa Voso, Sergio Amadori, Guillermo Sanz, Frederico Calado, Konstanze Döhner, Verena I Gaidzik, Michael Heuser, Torsten Haferlach, Marta Sobas, Amin T. Turki, Dirk Reinhardt, Rubén Villoria Medina, Michel van Speybroeck, Renate Schulze-Rath, Jesús M Hernández Rivas, Brian J.P Huntly, Hartmut Döhner, Gert J. Ossenkoppele, Castellani Gastone, Lars Bullinger

Blood (2021) 138 (Supplement 1): 3438.

https://doi.org/10.1182/blood-2021-152215

Published: 2021

Journal Articles

Outcome of Human Umbilical Cord Blood Stem Cell Transplantation (CBT) for Acute Myeloid Leukemia in Patients Achieving First Complete Remission after One Versus Two Induction Courses: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Arnon Nagler, Myriam Labopin, Jan J. Cornelissen, Edouard Forcade, Patrice Chevallier, Nathalie Fegueux, Jorge Sierra, Hélène Labussière-Wallet, Jennifer Byrne, Thomas Cluzeau, Didier Blaise, Frédéric Baron, Annalisa Ruggeri, Mohamad Mohty, Deborah Desmier

Blood (2021) 138 (Supplement 1): 3964.

https://doi.org/10.1182/blood-2021-144827

Published: 2021

Journal Articles

Midostaurin in Patients (Pts) with Newly Diagnosed FLT3 -Mutation Negative Acute Myeloid Leukemia (AML): Final Results and Measurable Residual Disease (MRD) Analyses from the Unify Trial

Blood (2021) 138 (Supplement 1): 1303.

https://doi.org/10.1182/blood-2021-148129

Published: 2021

Journal Articles

Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database

Blood (2021) 138 (Supplement 1): 608.

https://doi.org/10.1182/blood-2021-150766

Published: 2021

Journal Articles

CEBPA bZip mutations: just a single shot

Jorge Sierra, Josep F. Nomdedeu

Blood (2021) 138 (13): 1091–1092.

https://doi.org/10.1182/blood.2021011263

Published: 2021

Journal Articles

The Elevation of LIVER Enzymes in Patients with Atrial Fibrillation and COVID-19 Is a Marker of Bad Evolution and Mortality

Juan Jose Cerezo Manchado, MDPhD, Pável E Olivera, MD, María Dolores Lopez Abellan, Desiree Campoy Castaño, César A Velasquez, MD, Carlos Rodriguez Rojas, Veronica Ramos Arenas, Katia Flores, MD, Rubén Cárdenas Gámez, Luis García de Guadiana Romualdo, PhD, Teodoro Iturbe Hernandez, Jorge Sierra, MD, Ramón Salinas, MD PhD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-142451

Published: 2020

Journal Articles

Prospective Population-Based Analysis of Characteristics and Therapy Options in AML: The Case of Catalonia (PERIS Project)

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-139160

Published: 2020

Journal Articles

Validation of the European Leukemianet 2017 Prognostic Classification for Patients with De Novo Acute Myeloid Leukemia Treated with a Risk-Adapted Protocol (CETLAM 2012)

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-140670

Published: 2020

Journal Articles

Acute Myeloid Leukemia with Isocitrate Dehydrogenases (IDH) 1 and 2 Mutations. a Real-World Study from the European IDH Research Group

Giulia Maggioni, MD, Cristina Astrid Tentori, MD, Maria Teresa Voso, MD, Sonja Heibl, MD, Klaus H. Metzeler, MD, Jan Moritz Middeke, MD, Joana Desterro, Maria Carmo-Fonseca, Erica Travaglino, Paola Fazi, MD, Alfonso Piciocchi, MS, Annika Maria Dufour, PhD, Jordi Esteve, Marta Pratcorona, MD, Valentina Mancini, MD, Federico Lussana, MD, Karsten Spiekermann, Christian Thiede, MD, Friedrich Stolzel, MD, Aida Botelho de Sousa, Mar Tormo, Pamela Acha, Montserrat Arnan, Nicola Fracchiolla, MD, Marcus Hentrich, Christoph Sippel, Bernhard Heilmeier, Marcos Lemos, Albertina Nunes, Sonia Matos, Marina Diaz, Ana Garrido, MD, David Gallardo, MD, Susana Vives, MD, Olga Salamero, Elisabetta Todisco, MDPhD, Claudia Basilico, MD, Francesco Passamonti, Sigrid Machherndl-Spandl, MD, Lisa Pleyer, Jorge Sierra, Francesc Solé, PhD, Matteo Giovanni Della Porta, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-140494

Published: 2020

NARROW

Ubtf tandem Duplications Define a Novel Subtype of Acute Myeloid Leukemia Associated with Younger Age, WT1 Mutations and HOXA9 Marked Overexpression

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Phase 1 Clinical Trial of Memory-Enriched Academic HSP-CAR30 for the Treatment of Relapsed/Refractory Hodgkin Lymphoma and CD30 + T-Cell Lymphoma: Clinical and Biological Studies

Autologous Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia - a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration

RAS Mutations in Adult Acute Myeloid Leukemia (AML). Frequency, Mutational Spectrum, and Identification of a Comutation Bias for KRAS K117 ( TET2 / ASXL1 )

Bone Marrow WT1 mRNA Upregulation in Acute Myeloid Leukemia (AML) in Complete Molecular Remission (mCR): Understanding the Limitations and Advantages of WT1 As a Measurable Residual Disease (MRD) Target

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Follow-up of patients with R/R FLT3- mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation

Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study

Outcome of Human Umbilical Cord Blood Stem Cell Transplantation (CBT) for Acute Myeloid Leukemia in Patients Achieving First Complete Remission after One Versus Two Induction Courses: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Midostaurin in Patients (Pts) with Newly Diagnosed FLT3 -Mutation Negative Acute Myeloid Leukemia (AML): Final Results and Measurable Residual Disease (MRD) Analyses from the Unify Trial

Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database

CEBPA bZip mutations: just a single shot

The Elevation of LIVER Enzymes in Patients with Atrial Fibrillation and COVID-19 Is a Marker of Bad Evolution and Mortality

Prospective Population-Based Analysis of Characteristics and Therapy Options in AML: The Case of Catalonia (PERIS Project)

Validation of the European Leukemianet 2017 Prognostic Classification for Patients with De Novo Acute Myeloid Leukemia Treated with a Risk-Adapted Protocol (CETLAM 2012)

Acute Myeloid Leukemia with Isocitrate Dehydrogenases (IDH) 1 and 2 Mutations. a Real-World Study from the European IDH Research Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only